The increasing attention towards Precision Medicine, which is believed to yield better results for treatments undertaken, has greatly increased the demand for gene and protein expression profiling and usage for medical research and diagnosis of inflammatory, degenerative and cancer diseases.
PERSONA BIOMED’s technology offers proprietary Protein and Gene expression profiling methods under the brand name of Customized Medical Research Service (CMRS™), for the molecular diagnosis of cancer (melanoma, colorectal, breast, prostate) and metastasis development (brain and liver), but also of cardiovascular and endocrine-metabolic diseases (arrhythmia, coronary and peripheral vascular insufficiency, metabolic syndrome, osteoporosis, etc).
CMRS support individuals with the provision of unique and effective customized information on the occurrence and spread through family members of specific gene and protein expression patterns representing normal (physiological) or altered (pathophysiological) biomarkers of major diseases. CMRS are new in the marketplace because they are based on specific functional changes occurring at key pathogenic pathways of inflammatory and neoplastic disorders. This approach makes them patient-specific in design and at same time highly efficient by tailoring diagnostic information and therapeutic effects to each patient’s disease.
CMRS have been developed by PBM, and are supported by specialized laboratory developed tests (LDTs) intended for facilitating medical diagnosis and treatment decisions concerning the patient, and advising the patient on health and medical issues. However, CMRS are experimental at the moment and should be regarded as a personalized research on the individual for better understanding patient’s predisposition to oncological and non-oncological diseases, or the status of patient’s diseases. Positive or negative results of laboratory tests will be computationally processed in conjunction with available clinical and anthropometric data from the patient’ medical history, and integrated through a PBM Dx Algorithm™ for generating a report on the PBM’s CMRS. However, final diagnosis and optimal patient management will be responsibility of the caregiver.
|Code||CUSTOMIZED MEDICAL RESEARCH SERVICES
(PROMETASTATIC Dx™ BIOSCREENING for Patients with Oncological Diseases)
|ALERTING ON OCCULT CANCER IN PATIENTS UNDERGOING BARIATRIC SURGERY|
|ALERTING ON OCCULT CANCER IN PATIENTS UNDERGOING CHOLECYSTECTOMY|
|ALERTING ON HEPATIC METASTASIS PREDISPOSITION: LIVER PROMETASTATIC REACTION GENE PROFILING TEST.|
|MELANOMA PHENOTYPE: INFLAMMATION-DEPENDENT GENE EXPRESSION PROFILING TEST AND IMMUNOSCORING|
|BREAST CANCER PHENOTYPE: PROMETASTATIC GENE PROFILING TEST AND IMMUNOSCORING|
|Code||CUSTOMIZED MEDICAL RESEARCH SERVICES (For Patients with Non-oncological Diseases)|
|BONE REMODELING FACTOR BALANCE AND OSTEOPOROSIS MOLECULAR PATTERN|
|INFLAMMATION-ASSOCIATED ATRIAL FIBRILLATION AND RECURRENT ARRHYTHMIA|
|METABOLIC SYNDROME, INSULIN RESISTANCE LEVEL AND CARDIOVASCULAR RISK|